Uveal melanoma (UM) is the most common intraocular malignancy in adults. Recent advances highlight the role of tumor-derived extracellular vesicles (TEV) and circulating hybrid cells (CHC) in UM tumorigenesis. Bridged with liquid biopsies, a novel technology that has shown incredible performance in detecting cancer cells or products derived from tumors in bodily fluids, it can significantly impact disease management and outcome. The aim of this comprehensive literature review is to provide a summary of current knowledge and ongoing advances in posterior UM pathophysiology, diagnosis, and treatment. The first section of the manuscript discusses the complex and intricate role of TEVs and CHCs. The second part of this review delves into the epidemiology, etiology and risk factors, clinical presentation, and prognosis of UM. Third, current diagnostic methods, ensued by novel diagnostic tools for the early detection of UM, such as liquid biopsies and artificial intelligence-based technologies, are of paramount importance in this review. The fundamental principles, limits, and challenges associated with these diagnostic tools, as well as their potential as a tracker for disease progression, are discussed. Finally, a summary of current treatment modalities is provided, followed by an overview of ongoing preclinical and clinical research studies to provide further insights on potential biomolecular pathway alterations and therapeutic targets for the management of UM. This review is thus an important resource for all healthcare professionals, clinicians, and researchers working in the field of ocular oncology.

Phosphine-borane complexes are novel chemical entities with preclinical efficacy in neuronal and ophthalmic disease models. In vitro and in vivo studies showed that the metabolites of these compounds are capable of cleaving disulfide bonds implicated in the downstream effects of axonal injury. A difficulty in using standard in silico methods for studying these drugs is that most computational tools are not designed for borane-containing compounds. Using in silico and machine learning methodologies, the absorption-distribution properties of these unique compounds were assessed. Features examined with in silico methods included cellular permeability, octanol-water partition coefficient, blood-brain barrier permeability, oral absorption and serum protein binding. The resultant neural networks demonstrated an appropriate level of accuracy and were comparable to existing in silico methodologies. Specifically, they were able to reliably predict pharmacokinetic features of known boron-containing compounds. These methods predicted that phosphine-borane compounds and their metabolites meet the necessary pharmacokinetic features for orally active drug candidates. This study showed that the combination of standard in silico predictive and machine learning models with neural networks is effective in predicting pharmacokinetic features of novel boron-containing compounds as neuroprotective drugs.

Machine learning has transformed ophthalmology, particularly in predictive and discriminatory models for vitreoretinal pathologies. However, generative modeling, especially generative adversarial networks (GANs), remains underexplored. GANs consist of two neural networks—the generator and discriminator—that work in opposition to synthesize highly realistic images. These synthetic images can enhance diagnostic accuracy, expand the capabilities of imaging technologies, and predict treatment responses. GANs have already been applied to fundus imaging, optical coherence tomography (OCT), and fluorescein autofluorescence (FA). Despite their potential, GANs face challenges in reliability and accuracy. This review explores GAN architecture, their advantages over other deep learning models, and their clinical applications in retinal disease diagnosis and treatment monitoring. Furthermore, we discuss the limitations of current GAN models and propose novel applications combining GANs with OCT, OCT-angiography, fluorescein angiography, fundus imaging, electroretinograms, visual fields, and indocyanine green angiography.

Syphilis is a sexually transmitted disease caused by the spirochete Treponema pallidum and can affect any organ in the body including the eye or central nervous system.¹ Ocular involvement of neurosyphilis most frequently involves panuveitis but can also include retinal vasculitis, interstitial keratitis, or optic neuropathy.^2,3

Background: Neurodegenerative diseases can cause vision loss by damaging retinal ganglion cells in the optic nerve. Novel phosphine-borane compounds (PBs) can protect these cells from oxidative stress via the reduction of disulfide bonds. However, the specific targets of these compounds are unknown. Proteomic evidence suggests that myelin oligodendrocyte glycoprotein (MOG) is a potential target. MOG is of significant interest due to its role in anti-MOG optic neuritis syndrome. Methods: We used in silico modeling to explore the structural consequences of cleaving the extracellular domain MOG disulfide bond, both in isolation and in complex with anti-MOG antibodies. The potential binding of PBs to this bond was examined using molecular docking. Results: Cleaving the disulfide bond of MOG altered the structure of MOG dimers and reduced their energetic favorability by 46.13 kcal/mol. The energy profiles of anti-MOG antibody complexes were less favorable when the disulfide bond of MOG was reduced in the monomeric state by 55.21 kcal/mol, but the reverse was true in the dimeric state. PBs exhibited reducing capabilities with the MOG extracellular disulfide bond, with this best-scoring compound binding with an energy of −28.54 kcal/mol to the MOG monomer and −24.97 kcal/mol to the MOG dimer. Conclusions: These findings suggest that PBs can affect the structure of MOG dimers and the formation of antibody complexes by reducing the MOG disulfide bond. Structural changes in MOG could have implications for neurodegenerative diseases and anti-MOG syndrome.

Glaucoma management relies on lowering intraocular pressure (IOP), but determining the target reduction at presentation is challenging, particularly in normal-tension glaucoma (NTG). We developed and internally validated a neural network regression model using retrospective clinical data from Qiu et al. (2015), including 270 patients (118 with NTG). A single-layer artificial neural network with five nodes was trained in MATLAB R2024b using the Levenberg–Marquardt algorithm. Inputs included demographic, refractive, structural, and functional parameters, with IOP reduction as the output. Data were split into 65% training, 15% validation, and 20% testing, with training repeated 10 times. Model performance was strong and consistent (average RMSE: 1.90 ± 0.29 training, 2.18 ± 0.34 validation, 2.11 ± 0.30 testing; Pearson’s r: 0.92 ± 0.02, 0.88 ± 0.02, 0.88 ± 0.04). The best-performing model achieved RMSEs of 1.57, 2.90, and 1.77 with r values of 0.93, 0.91, and 0.93, respectively. Feature ablation revealed significant contributions from IOP, axial length, CCT, diagnosis, VCDR, spherical equivalent, mean deviation, and laterality. This study demonstrates that a simple neural network can reliably predict individualized IOP reduction targets, supporting personalized glaucoma management and improved outcomes.